Long-term safety study of SPT-300 for major depression
Part of Mental health clinical trials.
This study is for people who finished the earlier BUOY-1 study of SPT-300 and want to continue treatment. It tests the long-term safety and tolerability of SPT-300 for major depressive disorder, with or without anxious distress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You finished the prior BUOY-1 study and completed the final visit (Day 42).
- If you could become pregnant, you must not plan to get pregnant during the study, not be breastfeeding, and use highly effective birth control for 30 days after the last dose.
- You must be willing and able to avoid using drugs of abuse.
- You have not been told by the study team or your doctor that you should not participate.
- You followed the rules and treatment during the earlier BUOY-1 study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral medication, SPT-300, for people with major depressive disorder, even if they also have mild anxiety. The goal is to see if it helps improve mood safely.
This trial tests an investigational medication for adults with major depressive disorder who are currently taking an antidepressant but still have symptoms. It aims to see if adding this new drug can improve mood better than a placebo.
This study tests an investigational medication (CYB003) for people with major depression whose current antidepressant isn't working well enough. It looks at whether this treatment can help improve depression symptoms.
This trial tests a new medication (NBI-1065845) added to your current antidepressant to see if it helps maintain improvement in depression. It is for people whose depression hasn't fully responded to their current oral antidepressant.
This long-term study is for people who already completed an earlier trial of the experimental drug CYB003 for major depression and who stayed on their regular antidepressant. It looks at the safety and effects of taking CYB003 again over many months.
This study tests a new oral medication (NBI-1065845) added to your current antidepressant to see if it's safe and tolerable over a long period for people with depression that hasn't fully responded to treatment.
Hear when a new Major Depressive Disorder (MDD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.